This wiki has undergone a migration to Confluence found Here
Difference between revisions of "2017-04-13 Patient Care FHIR Call"
Jump to navigation
Jump to search
(→Zulip) |
(→Zulip) |
||
| Line 195: | Line 195: | ||
** PC recommends creating a logical/domain model - Kirt has started this work via [http://clinfhir.com/logicalModeller.html ClinFHIR] via Model Selector > Graft > Mapping tab | ** PC recommends creating a logical/domain model - Kirt has started this work via [http://clinfhir.com/logicalModeller.html ClinFHIR] via Model Selector > Graft > Mapping tab | ||
** Desire to have transfusions (blood transfusion) included in scope -- start more broadly with '''BiologicallyDerivedProduct''' | ** Desire to have transfusions (blood transfusion) included in scope -- start more broadly with '''BiologicallyDerivedProduct''' | ||
| − | ** Motion to support creation of a new "biologically derived product" resource proposal (which will be approved by PC once written): Eric/Stephen: | + | ** Motion to support creation of a new "biologically derived product" resource proposal (which will be approved by PC once written): Eric/Stephen: 10-0-0 |
=== gForge Change Requests === | === gForge Change Requests === | ||
Revision as of 21:42, 13 April 2017
Contents
Meeting Information
| Patient Care FHIR Resources Conference Call Location: Conference Call |
Date: 2017-04-13 Time: 5-6:30pm ET | ||
| Facilitator | Michelle M Miller | Note taker(s) | Michelle M Miller |
| Attendee | Name | Affiliation
| |
| Elaine Ayres | NIH/Department of Clinical Research Informatics | ||
| Pushpalatha Bhat | |||
| X | Stephen Chu | The Australian Digital Health Agency (ADHA) | |
| Evelyn Gallego | EMI Advisors LLC | ||
| X | Eric Haas | Haas Consulting | |
| X | Rob Hausam | Hausam Consulting LLC | |
| X | Laura Heermann-Langford | Intermountain Healthcare | |
| X | Emma Jones | Allscripts | |
| X | Russ Leftwich | InterSystems | |
| Tony Little | Optum 360 | ||
| Jay Lyle | Ockham Information Services LLC, VA | ||
| Russell McDonell | Telstra Health | ||
| Lloyd McKenzie | Gevity (HL7 Canada) | ||
| Larry McKnight | Cerner | ||
| X | Michelle M Miller | Cerner | |
| Lisa Nelson | Life Over Time Solutions | ||
| Viet Nguyen | Lockheed Martin, Systems Made Simple | ||
| M'Lynda Owens | Cognosante | ||
| Craig Parker | Intermountain Healthcare | ||
| X | Joe Quinn | Optum | |
| Simon Sum | Academy of Nutrition and Dietetics | ||
| Iona Thraen | Dept of Veterans Affairs | ||
| Serafina Versaggi | Dept of Veterans Affairs | ||
| X | Bob Milius | NMDP | |
| X | Kirt Schaper | CIBMTR | |
| Mike Padula | CHOP | ||
| X | Matt Prestegaard | ||
| Quorum Requirements Met: yes | |||
Agenda
Agenda Topics
- Agenda review
- Approve previous meeting minutes 2017-04-06_Patient_Care_FHIR_Call
- Motion: Stephen/Russ
- Transplant Material
- gForge change request
Supporting Information
- Tracker Issues - https://docs.google.com/a/lmckenzie.com/uc?id=0B285oCHDUr09Mzh3b09rMFhEV1E
- Resolve QA Warnings to have resource FMM > 0
- Resolve QA Information messages to achieve FMM = 3
- Maintain QA checklist
Minutes
Zulip
- Blood, Tissue, Organ Donation
- NMDP (National Marrow Donor Program) and CIBTMR (Center for International Blood and Marrow Transplant Research) would like to participate in helping develop a new resource for transplant material
- It would include things like bone marrow, cord blood, peripheral blood stem cells - and any new resource could also address solid organs and blood transfusion although not part of the initial use case
- Align with scope of ISBT128, the purpose of which is: to provide standards and guidance for the coding and labeling of medical products of human origin (MPHO): blood, cellular therapy, tissues, regenerated tissue, milk, fecal microbiota, topical products of human origin, in vivo diagnostic MPHO, and organs for transplant, as well as those plasma derivatives for which ABO is relevant. (we may want to extend the scope to “biological origin” rather than limiting to “human origin”)
- Previously, Patient Care had voted to create a new resource, per GF#8458
- Transplant material resource would have relationship to two things -- who gave it and who received it
- Also includes examples that might originate from a human, but then manipulated
- Map process/forms to existing resources; profile for transplantation; categorize patients as donor vs recipient/patient
- Specimen is only for diagnostic purposes; Device was considered/debated;
- Per OO ListServ, proposed boundaries included
- Device: a manufactured item that is used in the provision of healthcare without being substantially changed through that activity. The device may be a medical or non-medical device
- Substance: A homogeneous material with a definite composition
- BiologicallyDerivedProduct: material extracted from a living mammalian organism or that is still living
- Per OO ListServ, proposed boundaries included
- PC recommends creating a logical/domain model - Kirt has started this work via ClinFHIR via Model Selector > Graft > Mapping tab
- Desire to have transfusions (blood transfusion) included in scope -- start more broadly with BiologicallyDerivedProduct
- Motion to support creation of a new "biologically derived product" resource proposal (which will be approved by PC once written): Eric/Stephen: 10-0-0
gForge Change Requests
Adjourn
Adjourned at <hh:mm am/pm> <timezone>.
Meeting Outcomes
| Actions
|
Next Meeting/Preliminary Agenda Items
|
© 2012 Health Level Seven® International. All rights reserved.
